BCR/ABL possesses a deregulated tyrosine kinase activity that drives a number of downstream signaling pathways, confers survival and proliferation advantages and restrains apoptosis, thus contributing to the pathogenesis of CML [1]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.